Introduction
Omalizumab is a monoclonal antibody used in the treatment of allergic asthma and chronic idiopathic urticaria. It targets and binds to immunoglobulin E (IgE), which is involved in the allergic response. By binding to IgE, omalizumab helps reduce the allergic inflammation and symptoms associated with these conditions.
Uses
Omalizumab is primarily used for:
- Allergic Asthma: To manage severe asthma symptoms in patients who have a history of allergy-related asthma and whose symptoms are not adequately controlled with inhaled corticosteroids.
- Chronic Idiopathic Urticaria: To treat chronic hives (urticaria) not caused by a known allergen in patients who have not responded to antihistamines.
| Brand Name | Omalizumab |
|---|---|
| Type | |
| Weight | |
| Generic | Omalizumab |
| Manufacturer | |
| Available in | English বাংলা |
Mechanism of Action
Omalizumab works by binding to IgE antibodies in the bloodstream. This prevents IgE from attaching to its receptors on mast cells and basophils, which are involved in allergic reactions. By inhibiting IgE binding, omalizumab helps to reduce the inflammatory responses that lead to asthma symptoms and hives.
How Long Does It Take to Work?
The onset of action of omalizumab can vary. For asthma, patients may start to see improvement in symptoms within 2 to 4 weeks of starting treatment, though full benefits may take several months to become evident. For chronic idiopathic urticaria, symptom improvement may also be observed within a few weeks, with full effects taking longer to manifest.
Absorption
Omalizumab is administered subcutaneously. It has a bioavailability of approximately 62%, and peak plasma concentrations are typically reached within 7 to 8 days after administration.
Route of Elimination
Omalizumab is primarily eliminated through the reticuloendothelial system, with degradation occurring in the liver and spleen. It is not extensively metabolized and is excreted mainly through the feces.
Dosage
For subcutaneous (SC) administration only. Divide doses of more than 150 mg among more than one injection site to limit injections to not more than 150 mg per site.Asthma: omalizumab 75 to 375 mg SC every 2 or 4 weeks. Determine dose (mg) and dosing frequency by serum total IgE level (IU/mL), measured before the start of treatment, and body weight (kg). See the dose determination charts.
Nasal Polyps: omalizumab 75 to 600 mg SC every 2 or 4 weeks. Determine dose (mg) and dosing frequency by serum total IgE level (IU/mL), measured before the start of treatment, and body weight (kg). See the dose determination charts.
Chronic Spontaneous Urticaria: omalizumab 150 or 300 mg SC every 4 weeks. Dosing in CSU is not dependent on serum IgE level or body weight.
The dosage of omalizumab depends on the patient's weight and the severity of their condition:
- For Allergic Asthma: The typical dose ranges from 150 mg to 375 mg administered subcutaneously every 2 to 4 weeks, based on body weight and baseline IgE levels.
- For Chronic Idiopathic Urticaria: The recommended dose is 300 mg administered subcutaneously every 4 weeks.
Dosage adjustments should be based on clinical response and specific patient needs.
Administration
Omalizumab is administered via subcutaneous injection. Patients may receive injections in a healthcare setting, or in some cases, training may be provided for at-home administration. The injection site is typically the upper arm, thigh, or abdomen.
Side Effects
Common side effects of omalizumab include:
- Injection site reactions such as pain, redness, or swelling
- Headache
- Fatigue
- Rashes
Less common but more serious side effects include anaphylaxis and other hypersensitivity reactions.
Toxicity
Omalizumab has a generally favorable safety profile when used as prescribed. However, severe allergic reactions, including anaphylaxis, can occur. Patients should be monitored for signs of allergic reactions, particularly following the first few doses.
Precautions
Precautions include:
- Monitoring for signs of anaphylaxis during and after administration.
- Assessing patients for any history of severe allergic reactions or hypersensitivity.
Interaction
Omalizumab does not have significant drug interactions. However, it should be used cautiously with other medications that can affect immune responses or increase the risk of hypersensitivity reactions.
Disease Interaction
Omalizumab should be used with caution in patients with a history of severe allergic reactions, autoimmune diseases, or those receiving immunosuppressive therapy.
Drug Interaction
There are no major drug interactions with omalizumab. However, the use of concurrent medications for asthma or chronic urticaria should be managed carefully to avoid any additive effects or interactions.
Food Interactions
There are no known food interactions with omalizumab. It can be administered regardless of food intake.
Pregnancy Use
The safety of omalizumab during pregnancy is not well-established. It should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Consult a healthcare provider before use if pregnant or planning to become pregnant.
Lactation Use
It is not known whether omalizumab is excreted in human breast milk. Caution should be exercised when administering omalizumab to breastfeeding mothers. Consult a healthcare provider for advice on breastfeeding during treatment.
Acute Overdose
In the case of an acute overdose, symptoms may include increased frequency of side effects or adverse reactions. Immediate medical attention should be sought. Supportive care and monitoring are essential.
Contraindication
Omalizumab is contraindicated in patients with a known hypersensitivity to the drug or any of its components. It should not be used in place of emergency asthma medications or as a primary treatment for acute asthma symptoms.
Use Direction
Follow the prescribed dosage and administration instructions carefully. Regular follow-up with a healthcare provider is recommended to monitor effectiveness and adjust the treatment as needed.
Storage Conditions
Store omalizumab in its original packaging in a refrigerator at 2°C to 8°C (36°F to 46°F). Do not freeze. Keep out of reach of children and protect from light.
Volume of Distribution
The volume of distribution for omalizumab is approximately 5 to 10 liters, reflecting its distribution primarily in the blood and tissues.
Half Life
The half-life of omalizumab is approximately 26 days. This allows for less frequent dosing compared to many other medications.
Clearance
Omalizumab clearance is primarily through the reticuloendothelial system and involves metabolism in the liver and spleen. The overall clearance rate reflects its long half-life and extended therapeutic effects.
See in details version Omalizumab also Omalizumab in bangla
